To The Moon

Full story: https://grafa.com/en/news/australia/caprice-resources-begins-regional-drilling-and-expands-gold-zones Caprice Resources started a regional aircore drilling programme and reported new drill results that extended gold zones. The company's stock fell 2.86% to $0.068 following the announcement. The drilling aims to test the Break of Day trend and identify new mineralised zones for follow-up reverse circulation drilling. Caprice Resources (ASX:CRS) commenced regional aircore discovery drilling across the western half of the Island Project while returning new drill results that extended gold mineralisation. The fresh exploration push follows prior drilling success at the site, which previously yielded high-grade gold intersections down plunge at the Baxter target. "Aircore drilling i

Full story: https://grafa.com/en/news/australia/australian-ethical-funds-under-management-dip-to-14-43b Australian Ethical total FUM slipped to $14.43 billion as wholesale redemptions offset positive superannuation net flows. The company's share price traded up at $4.18 following the announcement. Management continues expanding its middle-market offering to drive long-term value for customers and shareholders. Australian Ethical Investment (ASX:AEF) reported funds under management of $14.43 billion for the quarter ended Sept. 30, down slightly from $14.50 billion at the end of FY26. The slight decline came as wholesale redemptions and market conditions offset $0.13 billion in positive superannuation net flows. "The first quarter demonstrated the continued momentum and resilience of our bus

Full story: https://grafa.com/en/news/australia/austco-healthcare-to-acquire-caretech-for-4m Austco Healthcare agrees to acquire 100% of CareTech Systems for up to $4 million. The transaction includes an upfront cash payment of $3 million funded through cash reserves and a new debt facility. CareTech brings a portfolio of lower-cost aged care systems and wireless products across roughly 200 sites. Austco Healthcare (ASX:AHC) has entered into a binding agreement to acquire 100% of Brisbane-based CareTech Systems for an estimated total consideration of $4 million. The purchase expands the company's nurse call portfolio with lower-cost aged care and wireless systems currently installed across approximately 200 sites. The acquisition delivers owned products and intellectual property rather tha

Full story: https://grafa.com/en/news/australia/mayne-pharma-resolves-imvexxy-patent-dispute-with-teva Mayne Pharma settled its US Paragraph IV patent litigation with Teva Pharmaceuticals USA concerning IMVEXXY. The resolution involved no upfront monetary payments or cash transfers between either company. Teva agreed to a potential market entry date for generic IMVEXXY on Sept. 2, 2032. Mayne Pharma (ASX:MYX) has settled its US patent litigation with Teva Pharmaceuticals USA over generic versions of the menopause treatment IMVEXXY. The agreement resolves ongoing litigation started in April 2020 and establishes a potential generic product entry date of Sept. 2, 2032. "Following our settlement with Sun Pharma announced on Sept. 30, today’s agreement with Teva Pharmaceuticals USA resolves all

Full story: https://grafa.com/en/news/australia/australia-to-hit-chinese-aluminium-with-70-tariffs The Trade Remedies Commission proposed tariffs of up to 70.4% on Chinese aluminium windows and doors following dumping findings. The investigation revealed local producers suffered $350 million in price undercut losses and $72.6 million in lost sales. The Australian government aims to protect domestic manufacturers from subsidised foreign competition distorting the $2.8 billion market. The Australian Trade Remedies Commission has recommended preliminary tariffs of up to 70.4% on Chinese aluminium window and door imports after finding dumped products caused material injury to local producers. Chinese exporters captured a 19% share of Australia's $2.8 billion annual aluminium window and door ma

Full story: https://grafa.com/en/news/australia/dimerix-completes-first-100-patients-in-action3-phase-3-trial Dimerix announced that the first 100 patients completed the two-year double-blind treatment phase in its global ACTION3 trial. The Dimerix share price fell 4.3% to $0.21 following the market announcement. Completing treatment for 100 patients helps reduce trial execution risk for the company's leading kidney treatment candidate. Dimerix (ASX:DXB) reached a clinical milestone after the first 100 patients finished two years of double-blind treatment in its global ACTION3 Phase 3 trial. This progress provides clinical data continuity after the study previously passed a formal analysis for futility. "The completion of the first 100 patients represents another important milestone for th

Full story: https://grafa.com/en/news/australia/coventry-group-delivers-5-4m-quarterly-ebitda Coventry Group's unaudited earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose 87% year-on-year to $5.4 million. Group sales increased 1.3% compared to the prior corresponding period to reach $100.1 million. Management attributed the earnings surge to lower operating costs and a 50 basis point margin expansion. Coventry Group (ASX:CYG) reported unaudited Q1 FY27 sales of $100.1 million and a pre-AASB16 EBITDA of $5.4 million. Operating expenses fell by $1.5 million, 3.9% lower than the prior corresponding period despite continued inflationary pressure on wages, rents and other costs. Within business divisions, trade distribution sales grew 6.9% to $62.5 million, while flu

Full story: https://grafa.com/en/news/australia/australia-unemployment-rate-rises-to-4-7-in-september The seasonally adjusted unemployment rate rose to 4.7% in September. Total employment fell by 39,000 people as part-time work declined. The Australian Bureau of Statistics noted a higher proportion of people remained unemployed compared to recent years. Australia’s seasonally adjusted unemployment rate reached 4.7% in September as the economy shed 39,000 jobs, according to the Australian Bureau of Statistics. The decline follows a drop in the employment-to-population ratio, which fell 0.3 percentage points to 63.6% after last month showed more people entering the workforce without finding jobs. "This month there were 39,000 less employed people and 9,000 more unemployed people," said ABS H

Full story: https://grafa.com/en/news/australia/firebrick-pharma-secures-philippines-approval-for-nasal-spray Firebrick Pharma has received approval from the Philippines Food and Drug Administration to market Nasodine Nasal Spray as an over-the-counter antiseptic drug. Following the regulatory update, the Firebrick Pharma share price was unchanged at $0.031. The company is partnering with SV More Corporation to prepare for the commercial product launch in the Philippines, targeted for early 2027. Firebrick Pharma (ASX:FRE) has secured marketing authorisation from the Philippines Food and Drug Administration for its Nasodine Nasal Spray as an over-the-counter antiseptic drug. This regulatory approval provides an immediate market pathway into Southeast Asia’s second-largest country, which ha

Full story: https://grafa.com/en/news/australia/helloworld-travel-expects-up-to-84m-earnings Helloworld Travel projects full-year underlying EBITDA to reach $78 million to $84 million for FY27. The guidance includes a planned $14 million contribution from the upcoming Crown Currency Exchange acquisition set for Oct. 30. Strong international travel demand and early forward bookings are driving a projected total transaction value of approximately $4.8 billion. Helloworld Travel (ASX:HLO) announced full-year FY27 guidance, expecting total transaction value to reach approximately $4.8 billion with underlying EBITDA of $78 million to $84 million. First-quarter total transaction value and underlying EBITDA matched prior corresponding period levels despite higher aviation fuel costs and ongoing c